Country: Evrópusambandið
Tungumál: enska
Heimild: EMA (European Medicines Agency)
radium (223Ra) dichloride
Bayer AG
V10XX03
radium Ra223 dichloride
Therapeutic radiopharmaceuticals
Prostatic Neoplasms
Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.
Revision: 14
Authorised
2013-11-13
27 B. PACKAGE LEAFLET 28 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT XOFIGO 1100 KBQ/ML SOLUTION FOR INJECTION radium Ra 223 dichloride This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor who will supervise the procedure. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Xofigo is and what it is used for 2. What you need to know before Xofigo is used 3. How Xofigo is used 4. Possible side effects 5. How Xofigo is stored 6. Contents of the pack and other information 1. WHAT XOFIGO IS AND WHAT IT IS USED FOR This medicine contains the active substance radium Ra 223 dichloride (radium-223 dichloride). Xofigo is used to treat adults with advanced castration-resistant prostate cancer in progression after at least two other cancer treatments apart from treatments to maintain reduced levels of male hormone (hormone therapy), or who cannot take any other cancer treatment. Castration-resistant prostate cancer is a cancer of the prostate (a gland of the male reproductive system) that does not respond to treatment that reduces male hormones. Xofigo is only used when the disease has spread to the bone but is not known to have spread to other internal organs, and is causing symptoms (e.g., pain). Xofigo contains the radioactive substance radium-223 which mimics the calcium found in bones. When injected into the patient, radium-223 reaches the bone where the cancer has spread to and emits short-range radiation (alpha particles) which kills the surrounding tumour cells. 2. WHAT YOU NEED TO KNOW BEFORE XOFIGO IS USED X Lestu allt skjalið
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Xofigo 1100 kBq/mL solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of solution contains 1100 kBq radium Ra 223 dichloride (radium-223 dichloride), corresponding to 0.58 ng radium-223 at the reference date. Radium is present in the solution as a free ion. Each vial contains 6 mL of solution (6.6 MBq radium-223 dichloride at the reference date). Radium-223 is an alpha particle-emitter with a half-life of 11.4 days. The specific activity of radium-223 is 1.9 MBq/ng. The six-stage-decay of radium-223 to lead-207 occurs via short-lived daughters, and is accompanied by a number of alpha, beta and gamma emissions with different energies and emission probabilities. The fraction of energy emitted from radium-223 and its daughters as alpha-particles is 95.3% (energy range of 5.0 - 7.5 MeV). The fraction emitted as beta-particles is 3.6% (average energies are 0.445 MeV and 0.492 MeV), and the fraction emitted as gamma-radiation is 1.1% (energy range of 0.01 - 1.27 MeV). FIGURE 1: RADIUM-223 DECAY CHAIN WITH PHYSICAL HALF-LIVES AND MODE OF DECAY: Excipients with known effect Each mL of solution contains 0.194 mmol (equivalent to 4.5 mg) of sodium. For the full list of excipients, see section 6.1. 3 3. PHARMACEUTICAL FORM Solution for injection. Clear, colourless isotonic solution with pH between 6.0 and 8.0. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Xofigo monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines o Lestu allt skjalið